stockportfolio.pro
Progyny, Inc. (PGNY)
Healthcare · Healthcare Plans · NasdaqGS
Progyny, Inc. revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.58M | $105.40M | $229.68M | $344.86M | $500.62M | $786.91M | $1.09B | $1.17B | $1.29B |
| Gross profit | $7.40M | $19.43M | $45.51M | $70.06M | $112.14M | $167.32M | $238.80M | $253.36M | $304.48M |
| Net income | $-12.45M | $661,000 | $-8.57M | $46.46M | $65.77M | $30.36M | $62.04M | $54.34M | $58.52M |
| Net margin | -25.6% | 0.6% | -3.7% | 13.5% | 13.1% | 3.9% | 5.7% | 4.7% | 4.5% |
Source: Progyny, Inc. SEC filings (10-K).
What growth is priced into PGNY stock?
At today's market cap of $2.02B, Progyny, Inc. is priced for free-cash-flow growth of about -1.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $191.78M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 40.4%/yr over the last five fiscal years and revenue 30.2%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 9 years of Progyny, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PGNY in your portfolio →
Progyny, Inc. financial history by metric
About Progyny, Inc.
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Progyny, Inc. — frequently asked questions
What is Progyny, Inc.'s revenue?
Progyny, Inc. (PGNY) reported revenue of $1.29B for fiscal year 2025, up 10.4% from the prior year, according to its SEC filings.
Is Progyny, Inc. profitable?
Yes. PGNY earned net income of $58.52M in fiscal 2025, a net margin of 4.5%.
What is PGNY's P/E ratio?
Progyny, Inc. trades at a price-to-earnings ratio of about 33.5 based on the latest data in our nightly-refreshed cache.
How fast is Progyny, Inc. growing?
PGNY's revenue grew at roughly 30.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Progyny, Inc. have?
As of fiscal year 2025, PGNY carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Progyny, Inc.'s gross margin?
PGNY's gross margin was 23.6% in fiscal 2025 — gross profit of $304.48M on revenue of $1.29B.
What is Progyny, Inc.'s market cap?
Progyny, Inc. (PGNY) has a market capitalization of about $2.02B, based on the latest data in our nightly-refreshed cache.
When does Progyny, Inc.'s fiscal year end?
PGNY's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into PGNY stock?
At today's market cap of $2.02B, Progyny, Inc. is priced for free-cash-flow growth of about -1.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $191.78M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 40.4%/yr over the last five fiscal years and revenue 30.2%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Progyny, Inc.'s official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.